Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1344-1357
Closed Access | Times Cited: 1090

Showing 26-50 of 1090 citing articles:

Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 111
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 96
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 96
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 91
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 74
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
Zoe J. Assaf, Wei Zou, Alexander D. Fine, et al.
Nature Medicine (2023) Vol. 29, Iss. 4, pp. 859-868
Open Access | Times Cited: 72
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 66
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 64
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Jarushka Naidoo, Scott Antonia, Yi‐Long Wu, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 5, pp. 657-663
Open Access | Times Cited: 62
Emerging evidence and treatment paradigm of non-small cell lung cancer
Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 58
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
Jie Lei, Jinbo Zhao, Li Gong, et al.
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1348-1348
Open Access | Times Cited: 52
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, et al.
Nature (2024) Vol. 627, Iss. 8004, pp. 646-655
Open Access | Times Cited: 35
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 29
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100841-100841
Open Access | Times Cited: 20
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
Yixin Zhou, Anlin Li, Hui Yu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241285-e241285
Open Access | Times Cited: 19
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
Lynette M. Sholl, Mark M. Awad, Upal Roy, et al.
Archives of Pathology & Laboratory Medicine (2024) Vol. 148, Iss. 7, pp. 757-774
Open Access | Times Cited: 17
Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis
Qian Liu, Zakari Shaibu, Aiguo Xu, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters
Zujun Que, Dan Qi, Yun Jung Yang, et al.
Cellular & Molecular Biology Letters (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Yuan Cheng, Tao Zhang, Qing Xu
MedComm (2021) Vol. 2, Iss. 4, pp. 692-729
Open Access | Times Cited: 81
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 654-669
Open Access | Times Cited: 77

Scroll to top